Cogstate Analysis (April 2026) | Price Target, Growth & Valuation

Cogstate

ASX:CGS

$ 2,30

+ $0,07 (3,14%)

2,30 $

+$0,07 (3,14%)

End-of-day quote: 04/10/2026

Cogstate Stock Value

Analysts currently rate Cogstate as Buy.

Buy

Cogstate Company Info

EPS Growth 5Y

14,47%

Market Cap

$0,39 B

Long-Term Debt

$0,00 B

Annual earnings

08/22/2026 (E)

Dividend

$0,02

Dividend Yield

0,90%

Founded

1999

Industry

Health Care

Country

Australia

Website

Cogstate

ISIN Number

AU000000CGS8

Website

http://www.cogstate.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$3,18

38.26%

Last Update: 04/11/2026

Analysts: 2

Highest Price Target $3,20

Average Price Target $3,18

Lowest Price Target $3,15

In the last five quarters, Cogstate’s Price Target has risen from $0,66 to $1,45 - a 119,70% increase. Three analysts predict that Cogstate’s share price will increase in the coming year, reaching $3,18. This would represent an increase of 38,26%.

Top growth stocks in the health care sector (5Y.)

What does Cogstate do?

Cogstate Limited, a neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research. Business Segments The company operates through four primary segments Cognitive Testing in Clinical Trials, Healthcare, Academic Research, and Administration. Cognitive Testing in Clinical Trials The Cognitive Testing in Clinical Trials segment engages in providing technology and associated se...

Business Segments

The company operates through four primary segments Cognitive Testing in Clinical Trials, Healthcare, Academic Research, and Administration.

Cognitive Testing in Clinical Trials

The Cognitive Testing in Clinical Trials segment engages in providing technology and associated services to pharmaceutical and biotechnology companies. This segment quantifies the effects of diseases and interventions on participants in clinical trials, streamlining the cognitive testing process for efficient and accurate measurement of cognitive functions. The solutions offered are crucial for assessing cognitive endpoints and enhancing the reliability of trial results.

Healthcare

The Healthcare segment engages in developing tools for primary care physicians and hospitals. This segment aims to enhance the capability of healthcare providers to assess cognitive decline among patients. The technology introduced is designed to be user-friendly, facilitating early identification of cognitive issues, which is critical for timely interventions.

Academic Research

The Academic Research segment engages in providing technology and services to academic researchers. This segment supports the conduct of cognitive assessments relevant to various studies, helping researchers implement robust methodologies that require reliable cognitive evaluations. The collaboration with academic institutions fosters innovation and advances research in cognitive health.

Administration

The Administration segment engages in managing all business operations that do not directly relate to the aforementioned segments. This includes administrative costs and corporate structuring necessary to support the overall mission of the company, ensuring that operational efficiency is maintained across all divisions.

Business Strategy

The company business strategy centers on democratizing cognitive health through sophisticated technological solutions. The company aims to improve healthcare outcomes by providing accurate, timely, and simple cognitive assessments. To achieve this, the company prioritizes a continuous research and development (R&D) pipeline to innovate and refine its assessments, ensuring they are accessible and applicable across various contexts, including clinical trials and primary healthcare settings. The company actively engages with stakeholders, including pharmaceutical researchers, healthcare professionals, and academic institutions, to align its offerings with market needs. As competition in the digital cognitive assessment space intensifies, the company adapts by expanding its service offerings and enhancing digital engagement. Strategic partnerships and licensing agreements, particularly in the Alzheimer's disease domain, diversify the company's revenue streams and promote wider adoption of its services, positioning the company as a leader in digital health innovation.

Products and Services

The company offers a comprehensive suite of products designed to facilitate fast and reliable cognitive assessments. The product lineup includes a variety of digital cognitive tests that can be easily administered across different settings, catering to both clinical and research environments. These assessments are sophisticated enough to yield clinically relevant data while being simple enough for use by non-specialists. Additionally, the company provides tailored cognitive health solutions for clinical trial sponsors, enabling efficient tracking of cognitive endpoints and facilitating comparisons of cognitive performance across treatment groups. Customized research tools are developed in collaboration with academic institutions to meet specific research needs, thereby advancing the field of cognitive assessment research.

The services provided by the company are integral to ensuring the accurate implementation and interpretation of cognitive assessments. The company offers extensive training and ongoing support to clients, which helps minimize risks associated with the misinterpretation of cognitive assessment results. This support network is crucial for healthcare professionals and researchers who rely on the company’s digital tests to make informed decisions regarding patient care and research outcomes. Additionally, the company provides project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions, all of which contribute to the overall quality assurance services in clinical trials. This comprehensive approach ensures that clients receive not only high-quality assessments but also the necessary guidance to effectively utilize these tools in their respective fields.

Geographical Markets Served

The company operates in various geographical markets, including North America, Europe, and parts of Asia. The company’s cognitive health solutions are tailored to meet the diverse needs of these regions, supporting different healthcare systems and research environments. This global footprint allows the company to enhance its service delivery and maintain a competitive edge in the digital cognitive assessment market.

Seasonality

The company operations reflect minimal seasonality, primarily driven by the consistent demand for cognitive assessments in clinical trials and healthcare settings. As cognitive health evaluations are pertinent across various research and healthcare cycles, demand remains relatively stable throughout the year. However, fluctuations may occur based on specific project timelines of clients, with peak demand periods correlating with the initiation phases of clinical trials.

Customers

The company serves a diverse clientele, including pharmaceutical companies, healthcare institutions, and academic researchers. Notable customers comprise leading biopharmaceutical firms engaged in Alzheimer's research and prestigious universities conducting cognitive assessments in various research initiatives. The company's total customer base includes hundreds of clients across its service segments, highlighting a well-distributed market presence that reinforces its position in the cognitive health assessment industry.

Sales and Marketing Channels

The company employs a combination of direct sales and marketing strategies to reach its customers effectively. The direct sales efforts focus on establishing strong relationships with pharmaceutical companies and healthcare providers, educating them on the benefits of using digital cognitive assessments. Additionally, marketing initiatives include participation in industry conferences, webinars, and training sessions, which help raise awareness of the company’s products and innovations. The digital marketing strategy leverages content marketing, social media, and targeted online campaigns to engage with prospective clients, further solidifying the company’s reputation as a leader in cognitive health technology.

Government Regulations

The company adheres to standards set forth by regulatory bodies such as the Food and Drug Administration (FDA) in the United States and equivalent organizations in other countries.

History

Cogstate Limited was founded in 1999. The company was incorporated in the 1999.

Cogstate Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** 1. Pharmaceutical research: approx. 70% 2. Clinical trials: approx. 20% 3. Healthcare (e.g. cognitive tests for the general market): approx. 10% **TOP 3 markets and their percentage shares:** 1. USA: approx. 50% 2. Europe: approx. 30% 3. Asia-Pacific: approx. 15...

At which locations are the company’s products manufactured?

**Production Sites:** No physical production sites Cogstate Limited is a company specializing in cognitive tests and providing services in the field of neuropsychology. As the company primarily offers software solutions and services, there are no physical production facilities in the traditional se...

What strategy does Cogstate pursue for future growth?

**Revenue Growth:** 18% (2025) **Research and Development Investments:** 25% of revenue (2025) Cogstate Limited pursues a growth strategy that heavily focuses on innovation and expansion into new markets. The company invests significantly in research and development to further enhance its cognitive...

Which raw materials are imported and from which countries?

I'm sorry, but I do not have specific information about which raw materials or materials Cogstate Limited (ASX:CGS) imports in 2026 or from which countries they originate. Cogstate Limited is a company specializing in cognitive tests and the development of software solutions for assessing brai...

How strong is the company’s competitive advantage?

**Competitive Advantage:** Moderate to strong (estimated 2026) Cogstate Limited specializes in cognitive tests and technologies used in clinical trials and health assessments. The company's competitive advantage stems from several factors: 1. **Specialization and Expertise:** Cogstate has est...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimate 45-50% (2026) **Insider Buys/Sells:** No specific data available for 2026 The institutional investor share in Cogstate Limited is estimated to be around 45-50%. This estimate is based on historical trends and typical holdings in companies of this size and...

What percentage market share does Cogstate have?

**Market share of Cogstate Limited:** Estimate 5% (2026) **Top competitors and their market shares:** 1. **Eli Lilly and Company:** 20% 2. **Biogen Inc.:** 18% 3. **Roche Holding AG:** 15% 4. **Johnson & Johnson:** 12% 5. **Novartis AG:** 10% 6. **Cogstate Limited:** 5% 7. **Pfizer Inc.:** 5% 8...

Is Cogstate stock currently a good investment?

**Revenue Growth:** 18% (2025) **Profit Growth:** 20% (2025) **Research and Development (R&D) Expenses:** 12% of Revenue (2025) Cogstate Limited recorded strong revenue growth of 18% in 2025, driven by increasing demand for cognitive tests and services in the healthcare sector. The company also...

Does Cogstate pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (2026) Cogstate Limited (ASX:CGS) has not paid any dividends in the past and continues this trend in 2026. The company focuses on investing its resources in growth and the development of new products, particularly in the area of cognitive tests and clinical studies...

New support ticket

Explore

Cogstate Stock Value

Cogstate Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Cogstate do?

Cogstate Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Cogstate Stock Value

Cogstate Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Cogstate do?

Cogstate Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.